Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
THE WOODLANDS, Texas, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that the United States Court of Appeals for the Federal Circuit summarily affirmed the ruling of the United States District Court for the Southern District of Texas in favor of the Company in the Company’s motions for summary judgment that Dr. Fisch failed to present sufficient evidence to be added as a co-inventor of U.S. Patent Nos. 7,737,185 and 7,759,360, covering therapeutic uses of enclomiphene, and that equitable estoppel barred Dr. Fisch's counterclaims seeking to be added as a co-inventor of the patents at issue, in its lawsuit against Dr. Harry Fisch.
About Repros Therapeutics Inc.®
Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.
For more information, please visit the Company’s website at http://www.reprosrx.com.
CONTACT: Investor Relations: Thomas Hoffmann The Trout Group (646) 378-2931 [email protected]
